KVUE Kenvue Inc

$KVUE $KMB — EUROPEAN UNION APPROVES KIMBERLY-CLARK'S ACQUISITION OF KENVUE CONFIRMED REGULATORY DEVELOPMENT: The European Commission has approved Kimberly-Clark's acquisition of Kenvue, subject to divestiture commitments. KEY DETAILS: • Approval follows an antitrust review. • Kimberly-Clark agreed to divest its feminine hygiene brands throughout the European Economic Area. • Affected brands include Kotex, Camelia, Record and Lidie. MARKET TAKEAWAY: The approval removes an important regulatory obstacle to the transaction. However, this does not mean the acquisition has closed. Investors should monitor remaining closing conditions, the timing of the divestitures and any additional regulatory requirements. For merger-arbitrage investors, regulatory progress can reduce transaction uncertainty without eliminating completion risk.

$KVUE: 38 days left in the $4.7M Skin360 settlement. No Claim ID? File without one. The suit alleges face scans in Illinois Dec 2019 to May 2023 without BIPA consent. Sworn statement only. Claim by Nov 25. Open Class Actions.

$KVUE: pick how you get paid in the Skin360 settlement. Venmo, Zelle, PayPal, digital Mastercard or check, but checks expire in 90 days with no replacement. Claim by Nov 25, hearing Dec 17. Open Class Actions.

$KVUE: two deadlines in the Skin360 BIPA settlement. Opt out or object by Nov 10, or file a claim by Nov 25. The $4.7M fund pays equal shares, sworn statement only, no proof needed. Open Class Actions.

$KVUE's EU review could expire Tuesday. Phase 1 runs 25 working days, not calendar days, so a Brussels holiday moves your closing date. That's most of why this one is hard to pin down.

$KVUE I obviously did not get the memo about the early dividend. I assume this has something to do with the sale of the company to Kimberly Clark?

$KVUE | Snapshot 📊⚡ • Business: Kenvue Inc. is the world’s largest pure-play consumer health company, operating high-margin brands in self-care, skin health, and essential wellness. • Financial Health & Pipeline: Stable defensive dividend yield with reliable free cash flow, capitalizing on steady global consumer demand across retail health categories. • Bias & Conviction: Bullish Channel Reversal | Moderate Conviction (Holding structural trendline support at $17.30 backed by 2027 call LEAPS sweep flow). 🎯 Key Levels: 🐂 Bull Trigger: $17.50 / $17.91 🚀 Targets: $19.50 / $21.00 / $22.00 🛡️ Support: $17.30 / $17.10 ⚠️ Risk: $15.00 / $14.00 🔥 Volume & Flow: • 🟢 Bullish long-term flow featuring $87.5K in 12/17/2027 $15C and $26.3K in 12/17/2027 $18C sweeps hitting the ask. #KVUE #consumerhealth #stocks #finance #hovdid

$KVUE catching a bid off its 50 DMA and about to retest this diagonal trendline. Will look good if it can get back inside the triangle.